# SEC Form 4

П

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

### OMB APPROVAL OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

1. Name and Addres Caveney Brian	1 0	)*	2. Issuer Name and Ticker or Trading Symbol <u>LABORATORY CORP OF AMERICA</u> <u>HOLDINGS</u> [ LH ]	(Check	tionship of Reporting Person all applicable) Director Officer (give title	erson(s) to Issuer 10% Owner Other (specify				
(Last) 531 SOUTH SPF	(First) (Middle) RING STREET		3. Date of Earliest Transaction (Month/Day/Year) 02/12/2019		below) SVP, Chief Medical	below) Officer				
Street) BURLINGTON NC 27215 (City) (State) (Zip)		27215 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date,		ction Instr.				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311. 4)
Common Stock	02/12/2019		М		233	Α	(1)	233	D	
Common Stock	02/12/2019		<b>F</b> <sup>(2)</sup>		82	D	\$146.59	151	D	

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriva Securi Acquir (A) or Dispos of (D)	erivative ecurities cquired s) or (D) str. 3, 4		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Unit	(1)	02/12/2019		М			233	(3)	(3)	Common Stock	233	\$ <mark>0</mark>	1,437 <sup>(4)</sup>	D	
Restricted Stock Unit	(1)	02/12/2019		Α		850		(5)	(5)	Common Stock	850	\$ <mark>0</mark>	2,287 <sup>(4)</sup>	D	
Restricted Stock Unit	(1)	02/12/2019		A		7,060		(5)	(5)	Common Stock	7,060	\$ <mark>0</mark>	9,347 <sup>(4)</sup>	D	
Non- qualified Stock Options <sup>(6)</sup>	\$146.59	02/12/2019		A		3,500		02/12/2020 <sup>(7)</sup>	02/11/2029	Common Stock	3,500	\$0	3,500	D	

#### **Explanation of Responses:**

1. Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

2. Stock withholding to satisfy tax withholding obligations.

3. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19.

4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

5. The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020.

6. Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

7. The option vests in three equal installments beginning on the date reflected in this column.

/s/ Sandra D. van der Vaart, Attorney-in-Fact for Brian

Caveney

02/14/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

-----

KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra D. van der Vaart attorney-in-fact and agent, in connection with the filing for the undersigned on Form 3, Form 4, and Form 5 under the Securities Act of 1934, as amended, including, without limiting the generality of the foregoing, to sign the Form 3, Form 4, and Form 5 with respect to the undersigned's holding of and transactions in securities issued by Laboratory Corporation of America Holdings, in the name and on behalf of the undersigned as an officer of Laboratory Corporation of America Holdings, and any amendments to the Form 3, Form 4, or Form 5 and any instrument, contract, document or other writing, of or in connection with the Form 3, Form 4, and Form 5 or amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, including this power of attorney, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorney-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, each acting alone, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall become effective immediately, and shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5, with respect to the undersigned's holdings of and transactions in securities issued by Laboratory Corporation of America Holdings, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has signed these presents this 11th day of February, 2019.

/s/ Brian Caveney Brian Caveney